Type your tag names separated by a space and hit enter

C1-esterase inhibitor, recombinant

General

Pronunciation:
C1 es-ter-ase in-hib-it-or re-kom-bin-ant


Trade Name(s)

  • Ruconest

Ther. Class.
replacement enzyme inhibitors

Pharm. Class.
enzyme inhibitors

Indications

Treatment of acute attacks of hereditary angioedema (HAE).

Action

Replaces malfunctioning or missing C1 esterase inhibitor in patients with HAE. Suppression of the contact activation system by C1-esterase inihibitor prevents the cascade of events that leads to attacks of angioedema in HAE that are marked by increased vascular permeability, swelling, edema and laryngospasm.

Therapeutic Effect(s):

Lessened severity of HAE.

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism and Excretion: Unknown.

Half-life: 2.4–2.7 hr.

TIME/ACTION PROFILE (symptom relief)

ROUTEONSETPEAKDURATION
IVwithin 1 hrunknown16–24 hr

Contraindication/Precautions

Contraindicated in:

  • Known/suspected hypersensitivity to rabbits/rabbit-derived products
  • Previous immediate hypersensitivity reactions to C1 esterase inhibitor preparations.

Use Cautiously in:

  • Risk factors for thrombotic events
  • OB: Lactation:Use during pregnancy/lactation only if clearly needed;
  • Pedi: Safe and effective use in children <13 yr has not been established, increased risk of adverse reactions in children 13–17 yr).

Adverse Reactions/Side Effects

CNS: headache (↑in children 13–17 yr)

EENT: oropharyngeal pain (↑ in children 13–17 yr)

CV: THROMBOEMBOLIC EVENTS

GI: abdominal pain (↑ in children 13–17 yr), diarrhea, nausea

Misc: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS AND EXACERBATION OF HAE

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

None noted.

Route/Dosage

IV: (Adults and adolescents ≥84 kg): 4200 IU, a second may be given if symptoms persist (not to exceed two doses/24 hr).

IV: (Adults and adolescents <84 kg): 50 IU/kg, a second may be given if symptoms persist (not to exceed two doses/24 hr).

Availability

Lyophilized powder for intravenous use (requires reconstitution): 2100 IU/vial

Assessment

  • Assess for signs (facial, laryngeal, or abdominal swelling, dyspnea, pain, nausea, vomiting, cramps, diarrhea) and frequency of HAE.
  • Monitor for signs and symptoms of severe hypersensitivity reactions (hives, urticaria, chest tightness, wheezing, hypotension, anaphylaxis) during or after injection.
  • Monitor for thromboembolic events in patients with risk factors (indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives, morbid obesity, immobility) during and after administration.

Potential Diagnoses

Implementation

IV Administration

  • Intermittent Infusion: Ensure c1 esterase inhibitor (recombinant) and diluent are at room temperature before mixing. Reconstitute by withdrawing 14 mL of Sterile Water for Injection. Add diluent slowly; avoid forceful impact on powder. Swirl slowly to mix; avoid foaming. Repeat with second vial. Solution should be clear and colorless; do not administer solutions that are discolored or contain particulate matter. Use solution immediately or may be refrigerated up to 8 hr; do not freeze.
  • Rate: Inject slowly over 5 min.
  • Y-Site IncompatibilityDo not mix with other medications or solutions.

Patient/Family Teaching

  • Explain purpose of medication to patient. Advise patient to read Patient Package Insert
  • May be self-administered with proper training. Patient must be able to recognize the signs and symptoms of HAE and must have the dexterity and comprehension to self-administer injection. Instruct patient using directions in Patient Package Insert. Advise patient to seek medical attention immediately in addition to injection due to potential. for laryngeal edema. Instruct patient to record lot number from vial. At first sign of HAE attack, prepare injection. Bring c1-esterase inhibitor with you to health care facility. Notify health care professional immediately if swelling does not decrease after injection.
  • Advise patient to notify health care professional immediately of signs of hypersensitivity reactions or thrombosis (new onset of swelling and pain in limbs or abdomen, new onset of chest pain, shortness of breath, loss of sensation or motor power, altered consciousness, vision, or speech) occur.
  • Caution patient to consult health care professional of planning to travel.
  • Advise female patients to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

Decrease in intensity of symptoms of HAE.

C1-esterase inhibitor, recombinant is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Learn more.

Citation

Quiring, Courtney, et al. "C1-esterase Inhibitor, Recombinant." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110160/all/C1_esterase_inhibitor__recombinant.
Quiring C, Sanoski CA, Vallerand AH. C1-esterase inhibitor, recombinant. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110160/all/C1_esterase_inhibitor__recombinant. Accessed April 20, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). C1-esterase inhibitor, recombinant. In Davis's Drug Guide. Available from https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110160/all/C1_esterase_inhibitor__recombinant
Quiring C, Sanoski CA, Vallerand AH. C1-esterase Inhibitor, Recombinant [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 April 20]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110160/all/C1_esterase_inhibitor__recombinant.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - C1-esterase inhibitor, recombinant ID - 110160 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110160/all/C1_esterase_inhibitor__recombinant PB - F.A. Davis Company ET - 16 DB - Pediatrics Central DP - Unbound Medicine ER -